Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): A feasibility study by Zwaenepoel, Karen et al.
Automation of ALK gene rearrangement testing with
fluorescence in situ hybridization (FISH): A feasibility
study
Karen Zwaenepoel, Dennis Merkle, Florian Cabillic, Erica Berg, Marc-Antoine
Belaud-Rotureau, Vittorio Grazioli, Olga Herelle, Michael Hummel, Michele
Le Calve, Dido Lenze, et al.
To cite this version:
Karen Zwaenepoel, Dennis Merkle, Florian Cabillic, Erica Berg, Marc-Antoine Belaud-
Rotureau, et al.. Automation of ALK gene rearrangement testing with fluorescence in situ
hybridization (FISH): A feasibility study. Experimental and Molecular Pathology, Elsevier,
2015, 98 (1), pp.113-118. <10.1016/j.yexmp.2015.01.005>. <hal-01116397>
HAL Id: hal-01116397
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01116397
Submitted on 22 Oct 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
   
1/20 
 
Title  
Automation of ALK gene rearrangement testing with Fluorescence in situ 
Hybridization (FISH): A feasibility study 
   
Authors and affiliations 
Karen Zwaenepoel1,*,+, Dennis Merkle2,*, Florian Cabillic 3, Erica Berg4, Marc-Antoine 
Belaud-Rotureau 3, Vittorio Grazioli5, Olga Herelle6, Michael Hummel4, Michele Le 
Calve3, Dido Lenze4, Stefanie Mende4, Patrick Pauwels1, Benoit Quilichini7, Elena 
Repetti5 
1 Antwerp University Hospital, Department of Pathology, Wilrijkstraat 10, 2650, Edegem, 
Belgium. 2 Abbott Molecular, Max-Planck-Ring 2, 65205, Wiesbaden, Germany. 3 University 
of Rennes 1, Faculty of Medicine, and the Service de Cytogénétique et Biologie Cellulaire, 
CHU de Rennes, rue Henri Le Guilloux, 35033, Rennes CEDEX 9, France. 4 Charite 
University Hospital Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, 
Germany. 5 Italian Center of Diagnostics, Laboratory of Molecular Biology and Genetics, Via 
Saint Bon 20, 20147 Milan, Italy. 6 Abbott Molecular, Rue de la Couture 12, 94518 Rungis, 
France. 7 Biomnis Laboratory, Laboratory of Cytogenetics, 17-19 av Tony Garnier, 69357 
Lyon, France.  
* KZ and DM contributed equally to this manuscript.  
+ Corresponding Author: Karen Zwaenepoel, Antwerp University Hospital, Department of 
Pathology, Wilrijkstraat 10, 2650 Edegem, Belgium. Phone: +32 3 8214755, Fax: +32 3 
8214753 E-mail: Karen.Zwaenepoel@uza.be 
 
Short title: ALK FISH semi-automation 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
   
2/20 
 
Abstract 
In the past several years we have observed a significant increase in our understanding of 
molecular mechanisms that drive lung cancer. Specifically in the non-small cell lung cancer 
sub-types, ALK gene rearrangements represent a sub-group of tumors that are targetable by 
the tyrosine kinase inhibitor Crizotinib, resulting in significant reductions in tumor burden. 
Phase II and III clinical trials were performed using an ALK break-apart FISH probe kit, 
making FISH the gold standard for identifying ALK rearrangements in patients. FISH is often 
considered a labor and cost intensive molecular technique, and in this study we aimed to 
demonstrate feasibility for automation of ALK FISH testing, to improve laboratory workflow 
and ease of testing. This involved automation of the pre-treatment steps of the ALK assay 
using various protocols on the VP 2000 instrument, and facilitating automated scanning of 
the fluorescent FISH specimens for simplified enumeration on various backend scanning and 
analysis systems. The results indicated that ALK FISH can be automated. Significantly, both 
the Ikoniscope and BioView system of automated FISH scanning and analysis systems 
provided a robust analysis algorithm to define ALK rearrangements. In addition, the BioView 
system facilitated consultation of difficult cases via the internet. 
 
Keywords: Fluorescence in situ hybridization, FISH, VP 2000, automation, BioView, ALK 
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Introduction 
In recent years there has been a dramatic increase in the identification of oncogenic driver 
mutations in non-small cell lung cancer (NSCLC)1. In the non-squamous NSCLC subtype two 
of these driver mutations; epidermal growth factor receptor (EGFR) and the anaplastic 
lymphoma kinase (ALK), can be targeted by the administration of small molecule tyrosine 
kinase inhibitors (TKI), gefitinib and erlotinib (for EGFR)2 and crizotinib (for ALK)3, all of which 
have demonstrated significant antitumor activity in their respective patient populations4-11. 
Specifically for the case ALK gene rearrangements, which were initially discovered in NSCLC 
in 200712, a relatively rapid clinical development occurred, with crizotinib gaining Food and 
Drug Administration (FDA) approval in the USA in 2011, followed by European Medicines 
Association (EMA) approval in 2012 (less than five years from discovery to approved 
therapy). Recently, the College of American Pathologists (CAP), International Association for 
the Study of Lung Cancer (IASLC) and Association for Molecular Pathology (AMP) published 
recommendations for detecting ALK gene rearrangements in patients with advanced, non-
squamous NSCLC, to select candidates for crizotinib therapy13. Selection of patients for 
crizotinib TKI therapy should be performed with an ALK fluorescent in situ hybridization 
(FISH) assay using dual-labelled break-apart probes. 
The Vysis ALK Break Apart FISH Probe Kit was utilized to identify ALK rearrangements in 
NSCLC patients in Phase II and III crizotinib trials, and was co-approved by the FDA as the 
companion diagnostic for crizotinib therapy selection. While other assay technologies are 
investigated, including; real-time polymerase chain reaction (RT-PCR)14,15, 
immunohistochemistry (IHC)16-18, and next-generation DNA sequencing (NGS)19, 20, there is a 
lack of clinical validation for these technologies in detecting crizotinib responders, and as 
such, FISH remains the gold standard technology for the detection of ALK rearrangements in 
NSCLC13,21. 
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FISH is often considered a complex, and labor intensive molecular technique, and therefore 
we aimed to study if workflow, and ease of interpretation improvements could be made for 
the ALK FISH molecular assay by; automating the front-end pretreatment of 20 formalin-fixed 
paraffin-embedded (FFPE) NSCLC tissue specimens for ALK FISH assaying, as well as, 
providing automated back-end fluorescence scanning, and interpretation algorithms for 
enumeration and analysis of the ALK FISH specimens. The pretreatment steps were 
performed using the VP 2000 instrument, investigating a number of different pretreatment 
protocols (see materials and methods), were-as the back-end scanning and analysis of ALK 
FISH cases was investigated by a number of automated fluorescence microscope scanning 
systems, including; Metasystems, Ikonisys and BioView. The results demonstrated that both 
front-end and back-end automation of ALK testing are possible, although the specific 
pretreatment reagents and protocol are critical to obtaining robust results. Different 
fluorescence scanning systems provide differing levels of interpretation capabilities, from; 
manual enumeration on scanned images to software assistant interpretation algorithms that 
are highly concordant with manual reading. Significant workflow possibilities were observed 
for the BioView instruments, as they allowed web-based consultation and comparison of 
difficult specimens. 
 
Materials and Methods 
NSCLC Tissue Specimens 
This study was approved by the University Hospital of Antwerp (UZA) Bioethical Committee 
and includes biopsy and surgical resection samples from 40 patients with advanced NSCLC 
that were referred for ALK gene rearrangement testing at the institute (UZA) between 2011 
and 2013. FFPE tissue blocks were cut on a microtome into serial 5 μm sections, floated 
onto positively charge microscope slides (Thermo Scientific, Waltham, USA), and sent to the 
four other study sites in Rennes, Berlin, Lyon and Milan. Each site obtained a single 
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specimen of each of the 40 patient samples. Prior to pretreatment, the slides were 
deparaffinated using Xylene on the VP 2000 instrument (Berlin, Lyon) or manually in coplin 
jars (Antwerp, Rennes and Milan). 
Manual FISH staining  of NSCLC FFPE specimens- Antwerp 
In Antwerp, manual FISH staining of FFPE sections was performed according to the 
manufacturers recommended protocol using the Vysis Paraffin Pretreatment IV & Post-
Hybridization Wash Buffer Kit (Abbott Molecular, USA) and the Vysis ALK Break Apart FISH 
probe kit (Abbott Molecular). 
Semi-automated FISH staining of NSCLC FFPE specimens- Rennes, Berlin and Lyon 
In Rennes and Berlin the Vysis Paraffin Pretreatment IV & Post-Hybridization Wash Buffer 
Kit (Abbott Molecular) was utilized on the VP 2000 instrument (Abbott Molecular), with the 
protocol as described in the product insert.   
In Lyon the VP 2000 Reagents; Pretreatment Reagent, Protease Buffer and Protease II 
(Abbott Molecular) were utilized on the VP 2000 instrument using following pretreatment 
protocol: 15 min incubation at 80°C with pretreatment solution following by 25 min incubation 
at 37°C using the Protease II solution. Post-hybridization washing was performed using a 
0.4XSSC, pH 7/0.3% NP-40 homebrewed solution (MP Biomedicals, Inc / Abbott Molecular) 
for 2 min at 73? C. 
Denaturation and hybridization of the Vysis ALK Break Apart FISH probe kit was performed 
according the instructions insert use using a Thermobrite (Abbott Molecular) in Rennes and 
Lyon, and on a Dako Hybridizer (Agilent Technologies , Hamburg, Germany) in Berlin. In 
Berlin, counterstaining was performed using the 4',6-diamidino-2-phenylindole (DAPI) 
counterstaining from Dako (Agilent Technologies), while Rennes and Lyon utilized the DAPI 
provided in the Vysis ALK Break Apart FISH probe kit (Abbott Molecular).  
Semi-automated FISH staining of NSCLC FFPE specimens- Milan 
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In Milan, Italy, a proprietary-homebrew protocol was utilized on the VP 2000. Pretreatment of 
the specimens occurred at 96? C for 15 min in a TrisEDTA solution (5mM Tris + 1mM EDTA, 
pH 7). Pepsin (Porcine gastric mucosa 3555 u, Sigma-Aldrich) treatment (0.01N HCl + 0.4% 
pepsin) was performed for 6 min at 37? C. Slides were washed in distilled water and let dry. 
Probes of the Vysis ALK Break Apart FISH probe kit were denatured for 1 min at 85? C, 
followed by overnight hybridization at 37? C using a Thermobrite (Abbott Molecular). For 
counterstaining, the Vectashield mounting medium with DAPI (Vector Labs, Peterborough, 
UK) was used. Post-hybridization washing was performed using a 2XSSC/0.3% NP-40 
homebrewed solution for 2 minutes at 73? C (Abbott Molecular). 
Interpretation of ALK Fluorescence in situ Hybridization 
In all cases, ALK FISH was performed using the Vysis ALK Break Apart FISH probe kit 
provided by Abbott Molecular. For interpretation of ALK FISH status, the recommended 
scoring protocol was followed; where specimens were classified as positive for an ALK gene 
rearrangement (ALK positive) when a minimum of 25 out 50 or a minimum of 15 out of 100 
tumor nuclei demonstrated a break apart and/or isolated fluorescent orange FISH signal. 
Study Protocol 
As ALK FISH automation was not established prior to the beginning of this study, two sets of 
specimens were prepared from tissue blocks that had previously been interpreted at the 
UZA. The first set of specimens contained ten ALK positive and ten ALK negative NSCLC 
specimens. These twenty specimens were sent to each study site, as a training set, along 
with the full enumeration and analysis results from Antwerp, in order to allow each lab to 
develop a back-end automation, or pseudo-automation protocol. Prior to processing the 
training set, each site ran a set of ProbeChek ALK Negative and ALK Positive Control Slides 
(Abbott Park, USA) were processed with the VP 2000 at each site. Successful pretreatment 
of these ProbeChek control slides with VP 2000 allowed each site to proceed with the 
training set specimens with the same automated protocol. Upon evaluation of the training 
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set, and concordant results at each site, a new set of blinded specimens was dispatched to 
allow for evaluation of the semi-automated protocol. Again at UZA, ten unique ALK positive 
and ten unique ALK negative NSCLC specimens were prepared. This test set of twenty 
specimens was then dispatched to each study site, without the results of the analysis. The 
test set was processed at each site using the respective semi-automation protocol, and 
results were compared between the sites to gauge the success of each protocol. 
Back-end scanning and interpretation of ALK FISH specimens- Antwerp 
At UZA, manual interpretation of the ALK FISH specimens was performed as defined in the 
Vysis ALK Break Apart FISH probe kit package insert provided by Abbott Molecular on a 
Olympus BX41 microscope (Olympus, Hamburg, Germany). The specimens were also 
analyzed on a BioView Allegro-Plus automated scanning and analysis system (Rehovot, 
Israel) which allowed for automated analysis of ALK FISH. This system is FDA cleared and 
CE marked for ALK automated imaging and analysis. The system is composed by a 
fluorescent microscope Olympus BX-61 with a motorized 8-slides stage (Allegro-Plus). Using 
an x10 objective and DAPI filter, the operator selected on average 10-20 fields of view (FOV) 
from each sample. The BioView system performed per FOV automated capture of DAPI, 
spectrum orange and spectrum green fluorophores in 19 focal layers using single band filters 
and x60 oil immersion objectives. After completion, the operator reviewed the images and 
drew circles around 50 tumor nuclei. Each selected nuclei was automatically classified by the 
BioView software as positive or negative according the signal pattern (defined by probe 
insert). Next, the operator reviewed the analyzed cells and, if needed, adjusted the 
classification. Upon evaluation of 50 cells, an automated report can be generated. In case an 
equivocal result was obtained, 50 additional cells were selected and reviewed by a second 
analyst.    
Back-end scanning and interpretation of ALK FISH specimens- Lyon 
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In Lyon, the specimens were analyzed using a BioView automated scanning platform, in 
analogy to the BioView workflow of Antwerp.  The tumors cells were enumerated by the 
analyst in two ways: manual scoring under microscope eyepiece and automated scoring 
allowed by Bioview software. 
Back-end scanning and interpretation of ALK FISH specimens- Rennes 
In Rennes, the specimens were analyzed with a fluorescence microscope Axio Imager Z1 
(Zeiss, Göttingen, Germany) and Isis imaging software (Metasystems, Altlussheim, 
Germany). The entire hybridized surface was screened using a double band-pass filter with 
an x63 objective to detect areas with abnormal patterns and to focus the scoring. FISH 
scoring was performed under both real-time conditions at the microscope and with the use of 
z-stack images. 
Back-end scanning and interpretation of ALK FISH specimens- Berlin 
In Berlin, for signal detection and enumeration an Axio Imager Z1 (Zeiss, Jena, Germany) 
and the Isis software (version 5.3.1, MetaSystems, Altlussheim, Germany) were employed. 
Images were captured manually and the specimens were then enumerated on a computer 
screening. 
Back-end scanning and interpretation of ALK FISH specimens- Milan 
In Milan, the specimens were analyzed using an lkonisys automated scanning platform, 
based on the Ikoniscope®/Ikonisoft Robotic Microscopy instrument (Ikonisys Inc. New 
Haven, CT USA). The instrument starts with an initial scan using an x4 objective and DAPI 
fluorescence channel to identify the tissue section present on the slide. This DAPI tissue 
image is used to delineate the region of interest, by reference to the H&E image of the tissue 
section. Upon scanning this area using a “low magnification” x20 objective with DAPI, 
spectrum orange and spectrum green fluorescence channels, the perimeter of each nucleus 
was delineated and the FISH 3q26 signals in the nucleus were counted. The nuclei were 
then ordered based on a combination of the number of FISH signals they contained and 
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cellular morphology, to select an area of good nuclear distribution representative of the signal 
distribution observed, for analysis at high magnification. Using a x100 objective 20 fields 
were then imaged in 11 focal planes with the three fluorescence channels. After nucleus 
delineation, single orange, single green and paired/fused FISH signals were automatically 
evaluated according the Vysis ALK Break Apart FISH probe kit package insert. Before a 
signal was accepted as “true” by the system, three dimensional structure of the potential 
FISH signals was analyzed for a number of quantitative features. Number and percentage of 
positive and negative cells were tabulated and presented, along with a gallery of all cells 
imaged, for expert review. Following confirmation of the 50 cells by the expert, a report was 
generated. If the result was equivocal, a second set of 50 cells was confirmed for inclusion in 
the analysis. 
Online specimen analysis using the BioView SoloWeb software application 
As a number of sites experienced difficulties with the front-end processing of the specimens, 
a novel FDA cleared web based application online software, SoloWeb, was provided by 
BioView to allow for remote  interpretation of the specimens that were successfully prepared 
with the manual protocol in UZA, Antwerp, and scanned with the BioView Allegro-Plus 
system using standard web browsers.  
 
Results 
Training Set  
Twenty NSCLC specimens, ten of which were ALK FISH negative (samples 01-10), and ten 
which were ALK FISH positive (sample 11-20), were processed manually in Antwerp. Serial 
sections of the same specimens were dispatched to four different European centers 
(Rennes, Lyon, Milan and Berlin) for automated front-end specimen processing with VP 
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2000, followed by manual analysis. Table 1 shows the results of the twenty training 
specimens at each site.  
Using the manual protocol, UZA demonstrated a 100% success rate on the samples 
processed. This was not the case for Rennes, Lyon and Berlin who could only process 12, 
13 and 17 of the 20 training set specimens, respectively. Milan had a 100% success rate, but 
did not report the results of the enumeration, as they utilized the results of Antwerp, as a 
benchmark to develop an automated ALK scoring algorithm on the Ikonisys system.     
The results indicated a high degree of variability in technical performance between the 
various protocols at each site. While the manual ALK FISH protocol demonstrated a robust 
and reproducible specimen pretreatment, the VP 2000 protocols utilized in Rennes and Lyon 
demonstrated significant FISH failure rates of 40% and 35%, respectively. Interestingly, in 
Berlin, where a nearly identical protocol was utilized as in Rennes, the FISH failure rate on 
the training set was merely 15%. In Milan, where a proprietary homebrew protocol was 
employed on the VP 2000, all specimens were processed successfully as judged from 
examination of FISH signals. Manual enumeration was not performed as the Milano lab sent 
the specimens to Ikonisys in order to build an automated analysis algorithm for use on the 
subsequent test set.  
 
Test Set 
As the training set had been deployed to assess the success of the front-end pretreatment 
protocol, and to allow for training of a back-end system, a new set of twenty blinded, serial 
NSCLC specimens were sent to each site. These specimens were processed manually in 
Antwerp, but the results were not shared with the sites. Each site then utilized their 
respective VP 2000 protocol for the front-end automation, and their respective back-end 
scanning protocol to elucidate the ALK status of each specimen.  
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Again, the manual pretreatment protocol was robust, although two of the ALK negative 
specimens (24 and 36) failed to processes adequately for interpretation, a consistent 
observation across all of the sites, except Milan. We observed VP 2000 results consistent to 
those of the training set in Lyon, Berlin and Rennes, where 30%, 20% and 20% of the 
specimens failed pretreatment respectively. In Milan, there was a 100% success rate on all 
of the specimens, again confirming the feasibility of a highly robust front-end automation 
protocol for ALK FISH on the VP 2000 instrument. 
With respect to the interpretation of the ALK FISH assay, two of the sites, Rennes and Berlin, 
utilized scanning systems to capture high resolution images, which were then enumerated 
manually on computer screens. In Antwerp, Lyon and Milan, fully automated back-end 
scanning analysis systems were employed.  
In Rennes, when the specimens were successfully pretreated, the concordance between 
positive and negative ALK FISH between the Rennes and Antwerp enumerations was 100%. 
In Berlin we observed two disconcordant cases (specimens 27 and 39), which were 
misclassified as ALK negative. Similar, in Lyon two cases (specimen 25 and 39) were 
misclassified as ALK negative. Specimen 27 and 39 were the two most challenging ALK 
positive cases of the test set as they both contained less than 30%  of cells with translocation 
(as determined by Antwerp, Rennes and Milan). 
Using automated analysis algorithms, the BioView system in Antwerp, as well as the Ikonisys 
system in Milan produced highly concordant results (100%) for all of the specimens that were 
successfully pretreated. Interestingly, in Milan, even the two cases that failed pretreatment at 
the other sites, produced ALK negative results.   
 
Reanalysis of difficult specimens using SoloWeb 
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Unfortunately a number of the specimens failed to be processed successfully on the VP 2000 
instrument in Lyon, Rennes and Berlin. We wanted to assess if these cases could potentially 
be remotely analyzed by each site if given access to the raw images utilizing an innovate 
software developed by BioView, called SoloWeb. The SoloWeb software allowed each of the 
three sites to log into the BioView captured cases from Antwerp and reinterpret each case 
over the internet. The results of this reanalysis are also presented in Table 2. With the 
exception of one case for Lyon (specimen 39) there was 100% concordance between the 
interpretations in Antwerp, Rennes, and Berlin. Interestingly, even the two disconcordant 
cases from Berlin’s manual computer image-based read and one of the two disconcordant 
cases from Lyon’s BioView based analysis, were correctly reclassified as ALK positive using 
the BioView-based analysis algorithms on the images of the tumor regions selected by 
Antwerp. 
 
Discussion  
In this study, we evaluated the feasibility for ALK FISH automation by comparing results of 
manual testing with those of automated testing. In a first phase of the study, 20 slides were 
sent to four European laboratories to assess the success of the front-end pretreatment 
protocol, and to allow for training of a back-end system. In a second phase, 20 blinded slides 
were sent to the participating laboratories to access their respective back-end scanning 
protocols. 
Taken together, the results of this study suggest that automation of ALK FISH on the VP 
2000 instrument is feasible; however the choice of pretreatment chemistry is critical to 
obtaining robust results, as the manual protocol reagents for NSCLC could not simply be 
adapted for the VP 2000 (23.75% failure), nor were the existing Abbott VP 2000 reagents at 
the time the study was performed suitable for lung specimens (30% failure). Meanwhile 
Abbott introduced a new VP 2000 Pretreatment kit optimized for use with lung tissue. Results 
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from Milan suggested that some specific pretreatment protocols on the VP 2000 could yield a 
robust front-end automation protocol. With respect to the interpretation of specimens 
successfully processed on the VP 2000, the (manual) interpretation of ALK FISH signals was 
highly consistent and robust, as only one of the 62 results observed (1.6%) did not 
correspond between all sites. These data are in agreement with the error rates observed by 
European Society of Pathology in two EQA round for ALK testing22. 
Results from the blinded test set suggest using computer assisted diagnostic algorithms to 
aid in the interpretation of ALK FISH, or manual analyzing captured images on a computer 
screen, can yield highly concordant results (93.6%; 88 of 92 informative analysis) to manual 
interpretation at a microscope in a dark room. We did observe a slight trend for the 
automated analysis systems to produce slightly higher percentages of ALK positive nuclei as 
opposed to the manual reading of the specimens; however this did not impact the overall 
classification of the specimens as ALK positive or negative.  
With the SoloWeb software and raw images obtained in Antwerp, remote analysis of the 
specimens who failed successful processing on the VP 2000 was performed in Rennes, 
Berlin and Lyon. As the SoloWeb software allows for sharing of images between international 
sites this software has the potential to serve as a collaborative or consultative tool. Similar to 
the SoloWeb software of BioView, Ikonisys offers a proprietary InoniWAN server for 
consultation and/or collaboration.   
During the remote analysis, two disconcordant cases from Berlin’s manual computer image-
based read and one of the two disconcordant cases from Lyon’s BioView analysis, were 
correctly reclassified as ALK positive, resulting in a concordance of 98.1% (53 of 54 analysis) 
compared to manual evaluation. This reduction of incorrect evaluations (from 6.4 to 1.9%) 
illustrates the importance of selecting suited areas for analysis when performing automated 
analysis.  During manual analysis, the analyst selects tumor areas (at lower magnification) 
and analysis the cells in this area (at high magnification) almost simultaneously. During 
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automated processing, these processes are separated in time. As the analyst cannot depend 
on (his short term memory of) the low magnification image to select tumor cells in the high 
magnification view, the selection of regions with high tumor content (at low magnification) 
has become crucial for correct automated ALK FISH analysis. To avoid this issue, both the 
BioView system as the Ikoniscope platform allow for scanning of the H&E slide and 
automatching of the H&E image to the 10x / 4x DAPI image of the FISH slide respectively. 
For challenging cases, this workflow is recommended, as this information facilitates the 
selection of the correct cell population by the analyst.  
Taken together this multicenter study demonstrates feasibility that the ALK FISH protocol can 
be semi-automated from the front-end processing, to the back-end interpretation and image 
capture of the specimens.  Computer assisted software algorithms can aid in the 
interpretation of ALK FISH specimens. This opens the door to automation of other relevant 
FISH analysis on FFPE material (e.g. HER2 amplification in breast pathology and ROS1 
translocation in lung pathology). 
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Tables 
Specimen Antwerp Rennes Lyon Berlin Milan 
01 Inf (0%) Inf (0%) Inf (0%) Inf (6%) Inf (un) 
02 Inf (4%) Fail Inf (2%) Fail Inf (un) 
03 Inf (2%) Inf (0%) Inf (0%) Inf (10%) Inf (un) 
04 Inf (0%) Inf (2%) Inf (0%) Inf (2%) Inf (un) 
05 Inf (4%) Inf (0%) Inf (0%) Inf (12%) Inf (un) 
06 Inf (2%) Inf (0%) Inf (0%) Inf (6%) Inf (un) 
07 Inf (0%) Fail Inf (0%) Inf (8%) Inf (un) 
08 Inf (6%) Inf (0%) Inf (0%) Inf (4%) Inf (un) 
09 Inf (0%) Inf (0%) Fail Inf (0%) Inf (un) 
10 Inf (0%) Fail Inf (0%) Fail Inf (un) 
11 Inf (62%) Inf (58%) Inf (21%) Inf (50%) Inf (un) 
12 Inf (62%) Inf (31%) Inf (14%) Inf (46%) Inf (un) 
13 Inf (64%) Inf (48%) Fail Inf (56%) Inf (un) 
14 Inf (68%) Fail Fail Inf (77%) Inf (un) 
15 Inf (80%) Inf (90%) Inf (82%) Inf (60%) Inf (un) 
16 Inf (46%) Inf (82%) Fail Inf (40%) Inf (un) 
17 Inf (40%) Fail Fail Inf (25%) Inf (un) 
18 Inf (100%) Fail Inf (85%) Fail Inf (un) 
19 Inf (20%) Fail Fail Inf (22%) Inf (un) 
20 Inf (86%) Fail Fail Inf (92%) Inf (un) 
Abbreviations: Inf = informative result, fail = uninformative result, un = undefined 
Table 1: ALK FISH results of training set specimens. Between brackets, the percentage 
of ALK FISH positive cells observed for each specimen, are represented.  
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Specimen 
Manual Automated SoloWeb 
Antwerp  Rennes Lyon  Berlin Milan Antwerp  Rennes  Lyon  Berlin  
21 2 14 0 6 2 6 8 1 8 
22 0 2 0 2 0 2 3 0 2 
23 74 54 Fail Fail 82 90 95 89 94 
24 Fail Fail Fail Fail 0 Fail Fail Fail Fail 
25 70 42 0 56 58 53 62 66 76 
26 64 44 70 84 74 80 87 100 96 
27 26 24 Fail 0 25 44 44 31 74 
28 0 0 0 0 2 14 7 0 4 
29 64 Fail 50 38 31 63 72 62 64 
30 0 0 0 6 4 4 0 0 4 
31 56 20 65 66 78 80 76 80 70 
32 2 0 0 6 2 4 7 0 4 
33 2 2 0 8 0 8 7 0 4 
34 68 40 70 84 54 90 90 87 82 
35 0 8 0 4 2 12 7 3 14 
36 Fail Fail Fail Fail 0 Fail Fail Fail Fail 
37 0 Fail 0 Fail 2 4 10 6 8 
38 64 30 80 66 78 96 90 94 78 
39 28 22 0 0 20 68 36 13 44 
40 74 28 Fail 90 94 96 91 96 97 
 
Table 2: Percentage ALK FISH positivity of test set specimens. Fail indicates that the 
specimen was not successfully pretreated and did not yield interpretable FISH signals. 
